Aligning digital CD8
+ scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma* Aims: To study programmed death ligand 1 (PD-L1) expression, tumour-infiltrating T lymphocytes (TILs) and the molecular context in patients with earlystage squamous cell lung carcinomas (SCCs).
Methods and results:
The study included samples from 40 patients (discovery cohort) and 29 patients (validation cohort) diagnosed with early-stage SCC. PD-L1 immunohistochemistry (IHC) was performed with three commercially available clones (E1L3N, SP263 and SP142). CD8 + TILs were scored with a digital algorithm. All tumours were analysed with targeted next-generation sequencing (NGS). Additionally, TP53 mutations were investigated with direct sequencing. In both cohorts, we observed a significant association between CD8 + TILs density and high PD-L1 IHC expression in tumour cells (TCs). Furthermore, high SP142 PD-L1 expression in immune cells (ICs) was also associated significantly with CD8 + TILs density. Therefore, CD8 + TILs density discriminated between patients with high versus low PD-L1 IHC expression with excellent sensitivity and specificity. Interestingly, the highest percentages of PD-L1-
Introduction
Most of the advances in the personalised treatment of non-small cell lung carcinomas (NSCLCs) have been confined to the treatment of patients with adenocarcinomas (ACs). Squamous cell carcinomas (SCCs) are addressed in lung cancer biomarker guidelines, but usually lack targetable drive alterations. 1 The arrival of immunotherapy is increasing interest into this subgroup, because of the good response to immune checkpoint inhibitors. 2 Although the importance of identifying potential immunotherapy responders accurately has never been greater, few areas in cancer biomarkers have been as contentious. 2, 3 It has been proposed that the mutational or neoantigen burden, together with the density of tumour-infiltrating T lymphocytes (TILs) and the high expression of programmed death ligand 1 (PD-L1) and CD8 + , defines a type of tumour microenvironment predictive of response to immune checkpoint inhibitors. 2, 4, 5 However, these data have been challenged because some of the proposed methodologies are both difficult to reproduce in the clinical setting and are applied usually as an isolated approach and tailored to a specific design [e.g. tissue microarrays, comprehensive sequencing, complicated immunohistochemistry (IHC) scoring algorithms or gene expression profiling] (reviewed in Gibney et al.
2 ). Therefore, it has been proposed that composite strategies might be more effective for the prediction of checkpoint inhibitors therapies. 1, 2, [6] [7] [8] [9] For example, a combination of two methods [PD-L1 IHC and mRNA analysis of interferon (IFN)-c] has been shown to improve not only the positive predictive value, but especially the negative predictive value (up to 97%) in NSCLC patients treated with durvalumab. 10, 11 This situation prompted us to investigate several alternatives to the situation outlined above that are easier to reconcile with clinical practice in a series of early-stage SCCs. To our knowledge, there has not been an independent assessment of the tumour microenvironment using our strategy [i.e. ready-to-use PD-L1 IHC, automated digital CD8 + TILs scoring and commercial targeted next-generation sequencing (NGS)].
Material and methods

P A T I E N T S A N D T I S S U E S A M P L E S
The Institutional Ethics Committee at Grupo HM Hospitales reviewed and approved this study and regulated the need for additional specific consent. A total of 40 consecutive patients with early-stage lung SCC who underwent surgery at Hospital Universitario HM Sanchinarro from October 2008 to February 2016 were considered (discovery cohort). A previously published similar series of 29 patients from Hospital Cl ınico San Carlos was used as a validation cohort. 12 The material available for all tumours was formalinfixed and paraffin-embedded (FFPE). All samples were reviewed according to the current World Health Organisation (WHO) 2015 classification by two thoracic pathologists (E.C. and A.C.). Because distinguishing SCCs from other histological types can appear extremely difficult by routine light microscopy, we used IHC as described previously 13 to ensure that only bona fide SCCs were considered (data not shown). Clinical data were retrieved from the patient medical records. Patient and tumour characteristics are summarised in Table 1 .
I M M U N O H I S T O C H E M I S T R Y
To estimate the expression of PD-L1 and the density of TILs, IHC was performed on whole FFPE freshly cut tissue sections of 4-lm thickness using an automated stainer (Benchmark ULTRA; Ventana Medical Systems, Tucson, AZ, USA) and the following primary antibodies in accordance with the manufacturer's recommendations: three anti-human PD-L1 rabbit monoclonal antibodies (clone SP263, ready to use, Ventana; clone SP142, ready to use, Ventana; and clone E1L3N, dilution 1:200, Cell Signaling, Danvers, MA, USA) and anti-CD8 rabbit monoclonal antibody (clone SP57, ready to use, Ventana). The OptiView Universal diaminobenzidene (DAB) IHC Detection Kit (Ventana) was used for anti-PD-L1 antibodies, whereas the anti-CD8 was visualised with the UltraView Universal DAB IHC Detection Kit (Ventana). Sections were counterstained with haematoxylin. For optimisation of the PD-L1 staining, a PD-L1-positive SCC was included in all the slides as an external positive control and alveolar macrophages were also considered as internal positive controls. The lung non-neoplastic parenchyma in each case was used as a negative control. For the TILs expression, on-slide human tonsil was used as a positive control.
Immunostains were evaluated independently by two pathologists (E.C. and A.C.) blinded to the clinical and pathological data. When a discrepancy was observed, a consensus was reached for the final score. Regarding PD-L1 IHC, the percentage of tumour cells (TCs) and tumour-infiltrating immune cells (ICs) with positive membranous AE cytoplasmic staining of any intensity was assessed and dichotomised as positive or negative for the 1, 5, 10, 25 and 50% cut-offs, according to the criteria used in the corresponding clinical trials. 14 We defined heterogeneity as the variance in staining between fields of view within a given section, as described previously. 15 Furthermore, we considered two different patterns: 'geographic heterogeneity' (heterogeneity at 940 magnification) and 'mosaic heterogeneity' (heterogeneity at 9200 magnification).
Sections stained for CD8 were scanned digitally (iScan Coreo; Ventana) with a 9 20 objective (0.46 lm/ pixel). The whole-section images were visualised using Ventana Virtuoso software (Ventana) and one field of view from each of the three compartments were outlined at 9200 magnification: intra-epithelial, peritumoral stroma and intratumoral stroma, as described previously. 16, 17 Subsequently, all selected areas were scored automatically using an off-label nuclear algorithm on the Ventana Virtuoso software (Ventana) (Figure 1 ). The density of CD8 + cells, calculated by dividing the number of positive cells by the size of the region (cells/mm 2 ), was recorded with the same approach used by other authors.
We performed a targeted NGS panel (Oncomine ™ Focus Assay; ThermoFisher Scientific, Fremont, CA, USA) for screening of mutations, copy number variations (CNVs) and fusions in 52 genes, using the Ion Torrent PGM ™ platform (ThermoFisher Scientific) (see Supporting information). Based on a previous report 19 linking specific mutations with neoepitope load, we also investigated TP53 by direct sequencing (see Supporting information).
S T A T I S T I C A L A N A L Y S I S
We evaluated the association between PD-L1 expression and clinicopathological features, CD8 + TILs and molecular alterations along with disease-free survival (DFS) and overall survival (OS). The concordance between the PD-L1 IHC clones was determined with Pearson's correlation coefficient (q). To assess concordance of scores between pathologists, intraclass correlation coefficients (ICCs) and Fleiss ϰ coefficient were calculated for each antibody. ICCs of 0.85 or higher and a ϰ coefficient of 0.8 or higher indicate almost perfect agreement, as described previously. 20 Frequencies were compared using Fisher's exact test. For comparison of continuous variables across PD-L1 expression thresholds, analysis of variance (ANOVA) was used. Receiver operating characteristic (ROC) curves were used to compare different marker cut-offs for CD8 + T cell density that correlated with high PD-L1 expression by different assays and in different tumoral compartments. Optimal cut-points were defined as maximising the sum of sensitivity and specificity of CD8 + T cell density as predictive markers of high PD-L1 expression. Survival analysis was performed using the Kaplan-Meier method via the logrank test. All analyses were performed in R version 3.2.3 (R Core Team, Vienna, Austria), were twosided, and P-values < 0.05 indicated statistical significance.
Results
P D -L 1 I H C E X P R E S S I O N
PD-L1 IHC expression with the three antibodies evaluated on TCs and ICs according to the different criteria used in clinical trials are presented in Table 2 , and a representative example is illustrated in Figure 2. In the discovery cohort, all positive tumours showed a spatial heterogenous staining pattern on 
Discovery cohort (n (55) 18 (45) 28 (70) 12 (30) SP263 16 (40) 24 (60) 24 (60) 16 (40) 30 (75) 10 (25) Considering the highest cut-off in TCs (≥ 50%), the interobserver concordance was excellent, with exactly the same values in both series (i.e. ϰ coefficient of 0.87 for E1L3N and 1 for SP263 and SP142). In both cohorts, there was a very good correlation between the E1L3N and the SP263 clones (q = 0.94 in the discovery set and q = 0.99 in the validation cohort), while a lower correlation was observed between the SP263 and SP142 antibodies (q = 0.88 in the discovery cohort versus q = 0.87 in the validation cohort). Interestingly, we noted a perfect agreement between the E1L3N and SP263 clones using the 50% cut-off in both cohorts. Unsurprisingly, the correlation between the antibodies was worse when considering ICs (discovery cohort: q = 0.88 between E1L3N and SP263 and q = 0.74 between E1L3N and SP142 and SP263 and SP142; validation cohort: q = 0.86 between E1L3N and SP263, q = 0.70 between E1L3N and SP142 and q = 0.68 between SP263 and SP142).
C O R R E L A T I O N O F P D -L 1 I H C E X P R E S S I O N W I T H C L I N I C O P A T H O L O G I C A L C H A R A C T E R I S T I C S
PD-L1 IHC expression in TCs with the three antibodies was higher in current smokers than in former smokers (discovery cohort, mean: 16.19 versus 3.11; P = 0.048 for E1L3N clone; mean: 22.57 versus 7.28; P = 0.064 for SP263 clone; and mean: 12.62 versus 0.33; P = 0.026 for SP142 clone). There was a similar trend in the validation cohort, but the results were not significant (data not shown). There were no other relevant associations.
C O R R E L A T I O N O F P D -L 1 I H C E X P R E S S I O N W I T H C D 8 + T I L S
We found that SCCs exhibited different topographic CD8 + TILs densities (peritumoral stroma, intratumoral Figure 3 . In the validation cohort, the results were strikingly similar in the intra-epithelial compartment. CD8 + /mm 2 TILs within the peritumoral stromal compartment ranged from 91 to 2721 (mean AE SD: 1070.31 AE 687.43); within the intratumoral stromal region ranged from 20 to 3023 (mean AE SD: 1061.62 AE 768.78); and within the intra-epithelial compartment ranged from eight to 2133 (mean AE SD: 243.55 AE 406.50). In the discovery cohort, we observed a significant association between both the intra-epithelial and the peritumoral stromal CD8 + TILs density and high (≥ 50%) PD-L1 IHC expression in TCs with the three clones ( Table 3 ). The intra-epithelial finding was replicated consistently in the validation cohort, but the peritumoral compartment data were observed only with the SP142 clone. Furthermore, high (≥ 10%) SP142 PD-L1 expression in ICs was associated significantly with intra-epithelial CD8 + TILs density in the discovery cohort and with peritumoral and intratumoral CD8 + TILs densities in the validation cohort (Table 3) .
In addition, ROC analyses were used to determine the optimal cut-off value for CD8 + TILs density that discriminates between patients with high versus low PD-L1 IHC expression. As illustrated in Figure 4A ,B, the presence of 416 CD8 + /mm 2 within the intraepithelial compartment had 94% specificity and 80% sensitivity for identifying patients with high (≥ 50%) E1L3N and SP263 PD-L1 expression in TCs. Regarding SP142 PD-L1 expression, a density of 527 CD8 + /mm 2 within the intra-epithelial compartment had a 94% specificity and 75% sensitivity ( Figure 4C ), whereas in the peritumoral stromal compartment, 2094 CD8 + / mm 2 was required for a 75% specificity and 100% sensitivity ( Figure 4D ). Using the above cut-off values, in the validation cohort the results were as follows. The presence of 416 CD8 + /mm 2 within the intraepithelial compartment had 88% specificity and 40% sensitivity for identifying patients with high (≥ 50%) E1L3N and SP263 PD-L1 expression in TCs. Regarding SP142 PD-L1 expression, a density of 527 CD8 + /mm 2 within the intra-epithelial compartment had 92% specificity and 67% sensitivity, whereas in the peritumoral stromal compartment the specificity and sensitivity were 33 and 92%, respectively.
C O R R E L A T I O N O F P D -L 1 I H C E X P R E S S I O N W I T H M O L E C U L A R A L T E R A T I O N S
Molecular alterations found in both cohorts are summarised in Table 4 . In the discovery cohort, five of 26 (19.2%) patients with molecular alterations exhibited both mutations and CNVs. Five of 10 (50%) tumours with CNVs showed copy number gains in more than one gene (data not shown). TP53 mutations were concurrent with PI3 kinase subunit alpha (PIK3CA) mutations in all four positive cases and with fibroblast growth factor receptor 1 (FGFR1), cyclin-dependent kinase 6 (CDK6), PIK3CA, protooncogene C-Myc (CMYC) or Erb-B2 receptor tyrosine kinase 2 (ERBB2) amplifications in one patient. In the validation cohort, six of 20 (30%) patients with molecular alterations showed both mutations and CNVs and three of nine (33.3%) tumours with CNVs exhibited gains in more than one gene (data not shown). TP53 mutations were also concurrent with PIK3CA mutations in two cases, with epidermal growth factor receptor (EGFR), cyclin D1 (CCND1), FGFR1 or ERBB2 amplifications in two patients and with PIK3CA or CMYC amplifications in one patient.
In the discovery cohort, comparative analyses revealed that only high (≥ 10%) SP142 PD-L1 IHC expression in ICs showed a non-significant correlation with TP53 mutations (P = 0.099). Interestingly, the highest percentages of PD-L1-positive TCs with the three antibodies were found in samples with CDK6 amplification (range: 60-90%) or with high amplification of CMYC (range: 60-80%). Conversely, cases with FGFR1 amplification were negative for all PD-L1 clones. In the validation cohort, CDK6 amplifications were not identified and the only case of high CMYC amplification was negative. One of two FGFR1-amplified cases was PD-L1-positive in TCs.
The highest percentages of PD-L1-positive TCs with the three antibodies were found in one of the samples with CCND1 and PIK3CA co-amplification.
In the discovery cohort, there were no significant differences in OS or DFS according to PD-L1, although high (≥ 50%) PD-L1 IHC expression in TCs assessed with the three antibodies showed a non-significant trend for better DFS (log-rank P = 0.103 for E1L3N and SP263, log-rank P = 0.173 for SP142). Regarding CD8 + TILs and using the mean value as cut-off, high intra-epithelial (≥ 242) CD8 + density was associated marginally with improved OS (log-rank P = 0.059) ( Figure 5A ), but was related significantly to DFS (log-rank P = 0.026) ( Figure 5B ). High peritumoral stroma and intratumoral stroma CD8 + densities were not associated with improved OS (log-rank P = 0.940 and 0.301, respectively) or DFS (log-rank P = 0.396 and 0.447, respectively). Survival differences were not observed in the validation cohort, due probably to the small sample size.
Discussion
In this study, we wanted to align PD-L1 IHC with the evaluation of TILs and the genomic annotation of early-stage SCCs for three main reasons. First, the lack of interclone, interlaboratory and interobserver uniformity in assay performance and assay interpretation, together with the frequent occurrence of heterogeneous expression, may preclude the use of PD-L1 IHC as a final predictive test for immune checkpoint inhibitors. 2, [21] [22] [23] [24] [25] [26] [27] [28] Although most published series, including the present study, show a reasonable concordance between the different PD-L1 clones, there are some differences. [29] [30] [31] [32] [33] Along these lines, it is worth emphasising that the PD-L1 expression levels have been correlated with response to anti-PD-1 or anti PD-L1 agents. 34, 35 Furthermore, due to heterogeneous expression, sensitivity in small biopsies has been challenged. 36 It has been proposed that staining Table 4 . of more than six fragments in small biopsies or one block in surgical specimens 15, 37 is needed to avoid underestimating the PD-L1 status. Unexpectedly, heterogeneity of PD-L1 expression was always present in our series. Considering (i) the reasons stated above, (ii) the small size and limited number of fragments of most lung biopsies and (iii) the lack of standardisation of the pre-analytical variables that can yield a falsenegative result in a number of cases, 38 it is probably wise to state that negative PD-L1 expression alone is not enough to exclude patients from treatment. 3 Therefore, a multiparametric model combining other biomarkers might best predict response to checkpoint inhibitors (see below).
Secondly, although in NSCLCs TILs scoring is becoming an established prognostic parameter [39] [40] [41] [42] [43] [44] [45] [46] [47] and PD-L1 expression is associated clearly with TILs, [47] [48] [49] [50] [51] [52] combining both markers in real clinical practice has remained elusive. In our opinion, the main reasons are the lack of standardisation of the assessment tools and the limited enthusiasm for retesting correlations or methodologies established by others (see below). Due to a series of factors which often coexist (i.e. use of tissue microarrays, manual scoring or scarcely available commercial algorithms), it is difficult to apply the findings published in the literature to the clinical reality. 16, 18, 37, 45, 49, 51, 53 For example, in a recent review of studies that focused on the assessment of TILs in NSCLCs, only 20% of them used whole sections and digital cut-offs for this purpose. 42 We showed that abundant CD8 + TILs were associated with high PD-L1 expression in TCs. Of all three compartments, the intra-epithelial infiltration correlated most clearly with PD-L1 expression, consistent with a recent report in lung ACs. 49 Therefore, this approach could be extrapolated to small biopsies, in which the amount of stroma is usually extremely scarce. In contradistinction with lung ACs (E. Conde, unpublished data), the overall solid pattern of growth of lung SCCs allowed for a somewhat easy separation of the three compartments with the image analysis software. Other authors have attempted successfully to use image analysers to quantitate CD8 + TILs, 18, 37, 54 including the use of modified nuclear algorithms, 50 ,55,56 but we believe that our experience with the digital methodology reported herein is unique. Although the main limitation of our study is that these small cohorts were not treated with checkpoint inhibitors, the perfect replication of the intraepithelial data validates further the validity of our results. To partially overcome the aforementioned shortcomings, we used whole-tissue sections and commercially available tools, so our findings could be replicated and validated elsewhere. As has been suggested, we believe that this approach (i.e. use of digital pathology and image analysis software on whole slides) could overcome the alleged lack of inter-and intra-observer reproducibility for both quantifying and localising TILs. 16, 40, 56 In agreement with other authors, higher CD8 + TILs were associated with a better prognosis in SCCs. 37, 39, 46, 50 Similarly, we observed a trend towards a better outcome in PD-L1-positive patients with SCCs. 37, 46, 47, 50, [57] [58] [59] [60] [61] Interestingly, in some of these latter series the survival benefit of PD-L1 expression (including ICs) or higher CD8 + TILs are lost or even reversed when only ACs or non-SCC are considered. 46, [57] [58] [59] 61 Nevertheless, the prognostic value of PD-L1 expression in NSCLCs is still under debate. 48, 49, 51, 59, [62] [63] [64] Thirdly, because (i) a synergistic therapeutic effect has been proposed for the combination of some targeted therapies and immune checkpoints inhibitors, 62 and (ii) 'broad molecular profiling' or 'multiplexed genetic sequencing panels' are being recommended in international guidelines, 65, 66 we hypothesised that an off-the-shelf targeted resequencing assay could help to + T tumour-infiltrating T lymphocyte (TIL) density. The P-values were calculated using the log-rank test.
predict the status of PD-L1 in SCCs. Although this strategy has been challenged in a small series of SCCs (n = 6), 67 several lines of evidence have highlighted the selective immune properties of individual (or limited) genomic alterations in NSCLCs. 9, [68] [69] [70] In addition, a recent report has determined the immunogenicity of some specific missense mutations in SCCs, 19 so we have also investigated one not included in the commercial panel (TP53). Overall, an expected variety of genomic alterations in SCCs were found in our study. 19, 60, [71] [72] [73] [74] [75] Findings should be interpreted with caution to avoid sample size bias (i.e. both cohorts are small and the number of patients with specific molecular alterations is limited), but they are consistent with previous observations (see below). Interestingly, SP142 PD-L1 IHC expression in ICs showed a non-significant trend with TP53 mutations. A very similar association has been described recently in surgically resected ACs studied with p53 IHC as a surrogate marker of the p53 status. 76 Accordingly, it has been proposed that scoring of PD-L1 ICs may increase the accuracy of PD-L1 expression. 9 In agreement with our results, high copy number levels of MYC have been shown to induce PD-L1 expression in several tumour types, 77 but there is no positive correlation between FGFR1 amplification and PD-L1 expression in lung SCCs. 78 Remarkably, our finding concerning the highest percentages of PD-L1-positive TCs being found in the patient with CDK6 amplification replicates gene expression profiling data, in which up-regulation of PD-L1 and CDK6 overlapped perfectly in the same group of SCCs. 79 In conclusion, if we assume that PD-L1 IHC interobserver agreement might be more challenging than the concordance between assays (or laboratories, for that matter), 23, 60 the methodologies presented herein could help refine SCC specimens with lower percentages of PD-L1-positive cells, or even those completely negative. The increasing popularity of digital pathology and targeted NGS could provide an opportunity to improve current biomarker algorithms through multiparametric selection of patients' candidates to immune checkpoint inhibitors.
